{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:59:36Z","timestamp":1794293976218,"version":"4.9.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina de Familia. SEMERGEN"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.semerg.2026.102692","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:53:24Z","timestamp":1770742404000},"page":"102692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral anticoagulation in patients with atrial fibrillation in Primary Care in Spain. Rationale, design and baseline data of the RACOVIR study"],"prefix":"10.1016","volume":"52","author":[{"given":"J.","family":"Polo-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Mic\u00f3-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Garc\u00eda-Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Romero-Vigara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Garc\u00eda-Matar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Segura-Fragoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Garc\u00eda-Ler\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"S\u00e1nchez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Santos-Altozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semerg.2026.102692_bib0165","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semerg.2026.102692_bib0170","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.recesp.2013.07.015","article-title":"Prevalence of atrial fibrillation in Spain. OFRECE study results","volume":"67","author":"G\u00f3mez-Doblas","year":"2014","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.semerg.2026.102692_bib0175","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.recesp.2011.08.008","article-title":"Patients with atrial fibrillation in a primary care setting: Val-FAAP study","volume":"65","author":"Barrios","year":"2012","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.semerg.2026.102692_bib0180","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14779072.2023.2272652","article-title":"Should atrial fibrillation be considered a vascular disease? The need for a comprehensive vascular approach","volume":"21","author":"Escobar-Cervantes","year":"2023","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.semerg.2026.102692_bib0185","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics \u2013 2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.semerg.2026.102692_bib0190","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semerg.2026.102692_bib0195","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.recesp.2015.04.017","article-title":"Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in Spain: the PAULA study","volume":"68","author":"Barrios","year":"2015","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.semerg.2026.102692_bib0200","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.recesp.2014.04.020","article-title":"Assessment of degree of anticoagulation control in patients with atrial fibrillation in primary health care in Galicia, Spain: ANFAGAL study","volume":"68","author":"Cinza-Sanjurjo","year":"2015","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.semerg.2026.102692_bib0205","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.recesp.2014.11.022","article-title":"Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors","volume":"68","author":"Anguita","year":"2015","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.semerg.2026.102692_bib0210","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.22397","article-title":"Quality of anticoagulation with vitamin K antagonists","volume":"38","author":"Bertomeu-Gonzalez","year":"2015","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.semerg.2026.102692_bib0215","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.rce.2018.04.020","article-title":"Factors associated with poor anticoagulation control with vitamin K antagonists among outpatients attended in Internal Medicine and Neurology. The ALADIN study","volume":"218","author":"Contreras Muruaga","year":"2018","journal-title":"Rev Clin Esp (Barc)"},{"key":"10.1016\/j.semerg.2026.102692_bib0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164076","article-title":"Quality of vitamin K antagonist control and1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry","volume":"11","author":"Haas","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.semerg.2026.102692_bib0225","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.semerg.2026.102692_bib0230","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.recesp.2021.07.012","article-title":"Epidemiology of atrial fibrillation-related ischemic stroke and its association with DOAC uptake in Spain: first national population-based study 2005 to 2018","volume":"75","author":"D\u00edaz-Guzm\u00e1n","year":"2022","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.semerg.2026.102692_bib0235","article-title":"Current situation of direct oral anticoagulants in primary care in Spain: positioning of SEMERGEN in 2023","volume":"50","author":"Polo-Garc\u00eda","year":"2024","journal-title":"Semergen"},{"key":"10.1016\/j.semerg.2026.102692_bib0240","series-title":"General criteria and recommendations for the use of direct oral anticoagulants (DOACs) in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Therapeutic Positioning Report. UT ACOD\/V5\/21112016","year":"2016"},{"key":"10.1016\/j.semerg.2026.102692_bib0245","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.rce.2023.03.007","article-title":"Patterns and outcomes of switching direct oral anticoagulants in non-valvular atrial fibrillation: a real-world experience from Spain","volume":"223","author":"Rodilla","year":"2023","journal-title":"Rev Clin Esp (Barc)"},{"key":"10.1016\/j.semerg.2026.102692_bib0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279297","article-title":"Clinical outcomes in patients with atrial fibrillation treated with DOACs in a specialized anticoagulation center: critical appraisal of real-world data","volume":"18","author":"Moret","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.semerg.2026.102692_bib0255","doi-asserted-by":"crossref","first-page":"1110036","DOI":"10.3389\/fphar.2023.1110036","article-title":"Sex and gender differences in the use of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in primary health care in Catalonia","volume":"14","author":"Giner-Soriano","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semerg.2026.102692_bib0260","doi-asserted-by":"crossref","first-page":"601","DOI":"10.5603\/CJ.a2022.0044","article-title":"Outcomes and predictive value of the 2 MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: the EMIR study","volume":"29","author":"Sanmart\u00edn Fern\u00e1ndez","year":"2022","journal-title":"Cardiol J"},{"key":"10.1016\/j.semerg.2026.102692_bib0265","first-page":"100913","article-title":"Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity","volume":"37","author":"Navarro-Almenzar","year":"2021","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.semerg.2026.102692_bib0270","doi-asserted-by":"crossref","first-page":"10993","DOI":"10.3390\/ijerph182010993","article-title":"Gender and socioeconomic inequality in the prescription of direct oral anticoagulants in patients with non-valvular atrial fibrillation in primary care in Catalonia (Fantas-TIC Study)","volume":"18","author":"Dalmau Llorca","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.semerg.2026.102692_bib0275","first-page":"1210","article-title":"Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"27","author":"Charlton","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.semerg.2026.102692_bib0280","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ijcard.2021.05.036","article-title":"Antithrombotic strategies in elderly patients with atrial fibrillation revascularized with drug-eluting stents: PACO-PCI (EPIC-15) registry","volume":"338","author":"De la Torre Hernandez","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.semerg.2026.102692_bib0285","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/16078454.2021.1892329","article-title":"Quality of life in patients with non-valvular atrial fibrillation treated with oral anticoagulants","volume":"26","author":"Gabilondo","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.semerg.2026.102692_bib0290","first-page":"9","article-title":"Stroke prevention in patients with atrial fibrillation. Improving protection in the COVID-19 era","volume":"21A","author":"Masjuan-Vallejo","year":"2021","journal-title":"Rev Esp Cardiol Supl"},{"key":"10.1016\/j.semerg.2026.102692_bib0295","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.semerg.2026.102692_bib0300","first-page":"61","article-title":"Functional evaluation: the Barthel Index","volume":"14","author":"Mahoney","year":"1965","journal-title":"Maryland State Med J"},{"key":"10.1016\/j.semerg.2026.102692_bib0305","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.medcli.2016.05.024","article-title":"Validation of satisfaction questionnaire ACTS in outpatients with atrial fibrillation treated with oral anticoagulants in Spain. ALADIN study","volume":"147","author":"Su\u00e1rez","year":"2016","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.semerg.2026.102692_bib0310","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.semerg.2017.09.005","article-title":"Differences in the management of patients with atrial fibrillation according to whether primary care or the specialist initiates treatment with direct oral anticoagulants. The SILVER-AP and BRONCE-AP studies","volume":"44","author":"de la Figuera","year":"2018","journal-title":"Semergen"},{"key":"10.1016\/j.semerg.2026.102692_bib0315","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.aprim.2017.05.009","article-title":"Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting. The SILVER-AP study","volume":"50","author":"de la Figuera","year":"2018","journal-title":"Aten Primaria"},{"key":"10.1016\/j.semerg.2026.102692_bib0320","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2022-0049","article-title":"Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban","volume":"12","author":"Mar\u00edn","year":"2023","journal-title":"J Comp Eff Res"}],"container-title":["Medicina de Familia. SEMERGEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359326000092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1138359326000092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:14:32Z","timestamp":1772723672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1138359326000092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1138359326000092"],"URL":"https:\/\/doi.org\/10.1016\/j.semerg.2026.102692","relation":{},"ISSN":["1138-3593"],"issn-type":[{"value":"1138-3593","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral anticoagulation in patients with atrial fibrillation in Primary Care in Spain. Rationale, design and baseline data of the RACOVIR study","name":"articletitle","label":"Article Title"},{"value":"Medicina de Familia. SEMERGEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semerg.2026.102692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de M\u00e9dicos de Atenci\u00f3n Primaria (SEMERGEN). Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102692"}}